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Abstract
Purpose To compare the identification rate of the sentinel
node in a 1-day protocol versus a 2-day protocol in patients
with a nonpalpable breast carcinoma.
Methods In the 1-day protocol an average dose of 120 MBq
99mTc-nanocolloid was injected intratumorally on the day of
surgery, and in the 2-day protocol an average dose of
370 MBq
99mTc-nanocolloid was injected intratumorally the
day before surgery. Both a gamma ray detection probe and
patent blue were used to locate the sentinel node.
Results In57of 67 patients (85%) treatedinthe1-dayprotocol
and in 51 of 56 patients (91%) treated in the 2-day protocol the
sentinel node was detected (p=0.311). Of the patients in the 1-
day protocol and the 2-day protocol, respectively, 18 (27%)
and 13 (23%) showed metastasis (p=0.975)
Conclusion There was no significant difference in the
identification rate of the sentinel node between the 1-day





Lymphatic mapping and sentinel lymph node (LN) biopsy
(SLNB) are reliable staging tools in the management of
patients with breast carcinoma. In particular, patients with
small, often nonpalpable breast carcinoma benefit from
SLNB instead of axillary dissection as only 7.8–28.5% of
patients with T1a-c breast carcinoma have tumour-positive
LNs [1]. Therefore, without SLNB 70–90% of axillary
dissections would be redundant in this particular group. In
order to avoid disabling morbidity associated with axillary
dissection such as lymphoedema, a successful SLNB is of
great importance.
Nonpalpable breast carcinomas are often difficult to
discern at surgery. Therefore a guide wire is usually placed
preoperatively in order to localize the tumour. It is
suggested that a guide wire placed intra- or peritumorally
could disturb the lymph drainage pattern and thereby
decrease the success rate of the SLNB [2].
Currently wide differences exist in SLNB protocols
used.
99mTc-Nanocolloid radiotracer, vital dye or both are
used as localizing pharmaceuticals, while injection routes
include intratumoral, peritumoral, intradermal and/or sub-
areolar injection. Injection of the localizing pharmaceutical
can be done either pre- or intraoperatively, on the same day
or the previous day [3, 4]. Lymphoscintigraphy can be
performed using either the dynamic and/or the static
technique [5]. In our hospital, both radiotracer and blue
dye are injected intratumorally in patients diagnosed with a
nonpalpable breast carcinoma. Therefore, in nonpalpable
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guided by ultrasound or stereotaxis.
Initially patients diagnosed with a nonpalpable breast
carcinoma were treated according to a 2-day protocol. This
protocol was chosen to increase the number of successful
SLNB due to the possibility of performing late nuclear
imaging [6]. The 1-day protocol was introduced to allow all
patients to be treated in day-care and to lower the radiation
burden. It was unclear if there was a difference in the
visualization and successful surgical removal of the sentinel
node between the 1-day and the 2-day protocol and if guide
wire placement influenced the success of SLNB.
The aim of this study was to compare the 1-day and 2-
day protocols with regard to the identification rate and
removal of the sentinel node in patients diagnosed with
nonpalpable breast cancer.
Materials and methods
In this retrospective, nonrandomized, cohort study, 123
patients with a nonpalpable breast carcinoma treated
between July 2002 and July 2008 were included. Women
with newly diagnosed primary, nonpalpable invasive breast
cancer undergoing tumour resection and SLNB were
eligible for the study. Exclusion criteria were previous
breast cancer in the same breast, pregnancy and palpable
breast cancer.
Before the introduction of a 1-day protocol, 56 patients
underwent SLNB according to a 2-day protocol. Patients in
the 2-day protocol received a median dose of 370 MBq
radiotracer in 0.5 cm
3 of water (range 80–550 MBq). The
1-day protocol was introduced to allow patients to be
treated in day-care and to lower the radiation burden. From
then on, 67 patients were included in the 1-day protocol.
The first 23 patients in the 1-day protocol received a dose
of 80 MBq radiotracer. Due to low visualization rates the
subsequent 44 patients received a median dose of 120 MBq
radiotracer (80–2 2 0M B q )i n0 . 5c m
3 of water. The
nanocolloid radiotracer consisted of at least 95% human
albumin colloid particles of ≤80 nm.
In both groups the radiotracer was injected intratumor-
ally guided by either ultrasound or stereotaxis depending
on the visibility of the tumour. Patients were asked to
massage their breast after injection of the tracer. Patients
in the 1-day protocol underwent lymphoscintigraphic
imaging after 10 min, and 1 and 2 hours, and patients in
the 2-day protocol underwent lymphoscintigraphic imag-
ing directly after injection and the next morning before
surgery to assess the migration of the radiotracer. After
finding the sentinel node on the static images the skin was
marked. Intraoperatively patients received a peritumoral
injection of patent blue at the site of the maximum count
found with the gammaprobe (Europrobe Strasbourg,
France). First, the SLNB was performed and subsequently
the primary tumour was excised, followed by histopatho-
logical analysis using regular H&E and immunohisto-
chemical staining. In case of failure of the SLNB a regular
axillary dissection was carried out.
The number of LNs seen on static imaging was
compared to the number found during surgery. The hot
and/or blue sentinel nodes were removed and when the
exact location of the sentinel node was unclear intra-
operatively the second echelon nodes were removed as
well. The nodes both inside and outside the axilla were
removed. The SLNB was considered successful if the tissue
removed during surgery was hot and/or blue and proved to
be LN tissue on histopathological assessment. The lym-
phoscintigraphic visualization rate and the surgical success
rate were compared between the 1-day protocol and the 2-
day protocol. The success rate of the SLNB in patients with
a guide wire placed intratumorally before injection of the
radiotracer in the 1-day protocol or the 2-day protocol was
compared with that in patients without a guide wire in place
during administration of the radiotracer.
Statistics
Identification and removal of one or more sentinel nodes
was considered a successful SLNB. The successful removal
of the sentinel node, the proportion of patients with LNs on
scintigraphy and the difference in success rate of SLNB in
patients with a guide wire in place during injection of the
radiotracer between the two protocols were compared using
the chi-squared test; p<0.05 was considered significant.
The numbers of sentinel nodes seen on the preoperative
images and number of LN removed during surgery were
compared using the independent sample t-test; p<0.05 was
considered significant.
Results
The baseline characteristics in both groups were compara-
ble, except for tumour morphology (Table 1).
The visualization rate in the 1-day protocol was 61/67
(91%) and the visualization rate in the 2-day protocol was
55/56 (98%; p=0.087). The mean number of nodes seen
preoperatively was 1.48 (range 0–5) in the 1-day protocol
and 1.88 in the 2-day protocol (p=0.007). The visualization
rates in the two protocols for nodes outside the axilla were
similar (Table 2).
The surgical success rate of the SLNB was 57/67
( 8 5 % )i nt h e1 - d a yp r o t o c o la n d5 1 / 5 6( 9 1 % )i nt h e2 -
day protocol (p=0.311). The mean numbers of nodes
r e m o v e dw e r e1 . 6 4( r a n g e0 –6) in the 1-day protocol and
1384 Eur J Nucl Med Mol Imaging (2009) 36:1383–13871.61 (range 0–4) in the 2-day protocol (p=0.209). After
finding LNs on preoperative static imaging, the mean
numbers of LNs not found during surgery was 0.28 (range
0–3) in the 1-day protocol and 0.41 (range 0–4) in the 2-
day protocol (p=0.664). The numbers of nodes found
assisted by patent blue only was 4 in the 1-day protocol
and 5 in the 2-day protocol (not significant, p=0.73). The
numbers of nodes found assisted by the radiotracer and/or
patent blue in the 1-day protocol and in the 2-day protocol
did not differ significantly (see Table 2). Of the non-
visualized sentinel nodes, 1/6 (17%) in the 1-day protocol
and 1/1 (100%) in the 2-day protocol were found using
patent blue.
Of the patients in the 1-day protocol, 49 (73%)
showed no metastasis in the sentinel node, 3 had isolated
tumour cells (4.5%), 3 (4.5%) had micrometastases
(i.e. <2 mm) and 12 (18%) showed macrometastases
(i.e. >2 mm). Of the patients in the 2-day protocol, 42
(76.4%) showed no metastases, 1 (1.8%) had isolated
tumour cells, 3 (6%) had micrometastases and 9 (16.4%)
showed macrometastases. The number of metastases in
the patients in the two protocols did not differ signifi-
cantly (p=0.975).
In the 1-day protocol the first 23 patients had a
median dose of 80 MBq of radiotracer. After excluding
these patients, the success rate of the SLNB was 88%. In
29 of 67 patients (43%) in the 1-day protocol and in 15
of the 56 patients (26%) in the 2-day protocol, a guide
wire was in place when the radiotracer was injected. As
s h o w ni nT a b l e3, the presence of a guide wire during
injection of the radiotracer did not influence the success
rate of the SLNB.
Sentinel node 1-day protocol 2-day protocol (%) p
Nodes visualized by static lymphoscintigraphy 0.530
Axillary 59 (88%) 53 (95%)
Intramammary 2 (3%) 2 (5%)
Internal mammary chain 9 (13%) 4 (7%)
Mean number 1.48 1.88 0.007
Visualization rate 61 (91%) 55 (98%) 0.087
Nodes retrieved at surgery 0.524
Hot not blue 23 18
Blue not hot 4 5
Blue and hot 31 29
Mean number 1.64 1.61 0.209
Table 2 Characteristics of the
sentinel lymph node procedure
Baseline characteristics 1-day protocol 2-day protocol p value
Number of patients 67 56
Number of tumours 68 59
Median age (years) 59 59.5 0.955
Median size of primary (mm) 13 12 0.188
Histology 0.006
Ductal 53 (77%) 56 (95%)
Lobular 5 (7.1%) 1 (1.7%)
Ductolobular 8 (11.4%) 1 (1.7%)
Mucinous 1 (1.4%) 1 (1.7%)
Papillary 1 (1.4%) 0
Quadrant tumours 0.119
Retroareolar 5 (7.4%) 10 (18%)
Lateral upper quadrant 35 (52.2%) 26 (44%)
Medial upper quadrant 7 (10.2%) 10 (18%)
Lateral lower quadrant 10 (14.7%) 6 (11%)
Medial lower quadrant 12 (18.0%) 5 (9%)
Table 1 Baseline characteristics
Eur J Nucl Med Mol Imaging (2009) 36:1383–1387 1385Discussion
In this retrospective comparison of two historical cohorts of
patients who underwent lymphoscintigraphy in a 1-day or a
2-day protocol we did not observe statistically significant
differences in the identification and removal of the sentinel
nodes. No significant difference in location of the sentinel
node was found between the two protocols. Moreover, the
presence of a guide wire when injecting the radiotracer did
not influence the success rate of the SLNB.
There were some weaknesses in this study. A relatively
small number of patients were retrospectively included.
Therefore there are some possible confounders that could
have influenced the results. In both protocols patients had
a guide wire in place during injection of the radiotracer. It
has been suggested that the presence of a guide wire can
disturb the regular draining pattern and radiotracer can
leak past the guide wire [2]. The numbers of guide wires
in place during injection of radiotracer were comparable
between the two groups. We could not demonstrate a
negative influence of a guide wire placed intratumorally
before injection of the radiotracer.
Next, the dosage of radiotracer injected in the 1-day
protocol differed. It is suggested that a mean dose of at least
90 MBq radiotracer is needed for adequate lymphoscintig-
raphy [7, 8]. Possibly the higher dose of radiotracer, after
excluding the first 23 patients in the 1-day protocol,
resulted in the observed higher success rate of SLNB as is
suggested in the literature [9]. Nevertheless, this study was
nonrandomized and firm conclusions on this subject are not
justified. In order to facilitate an adequate injection volume
in both groups the total injected volume was 0.5 cm
3.
Therefore, the dilution of the radiotracer was different in
the two protocols. Although there is no consensus on the
volume and dilution in the current literature, the difference
in dilution could have influenced the drainage patterns and
speed [10].
The patients treated in the 1-day protocol underwent
lymphoscintigraphy up to 2 h after injection. In the
literature, imaging up to 4 h after injection is described.
Possibly, late imaging could increase the number of
visualized nodes, and thereby improve the success rate of
the SLNB. Finally, the success rates found in this study
were lower than the rates of 90–99% reported in the
literature [8, 11–13].
To our knowledge, this is the first study to compare
success rates between a 1-day and a 2-day protocol in
nonpalpable breast cancer. Furthermore, this study provides
a concise answer to a practical question. Studies performed
so far included both patients with palpable and nonpalpable
breast cancer. Although the protocols in these studies
differed (i.e. particle size and injection region) they also
showed no differences between a 1-day and a 2-day
protocol [6–9]. As has been shown previously, the
combination of a radiotracer preoperatively and dye
injection peroperatively was superior to the use of radio-
tracer or dye only [3, 14]. In our study, in the 1-day
protocol in four patients (6%) and in the 2-day protocol in
five patients (9%), the sentinel node was found with patent
blue only. This indicates the importance of the combination
technique. In cases of non-visualization preoperatively,
surgeons can still rely on the patent blue [15].
The site of injection of the radiotracer is a matter of
discussion. In our protocol the radiotracer was injected
intratumorally, using either ultrasound or stereotactic
guidance. As reported by others, intra-/peritumoral injec-
tion of the radiotracer and the patent blue is as reliable as
subareolar injection [16]. After intratumoral injection,
more of the internal mammary chain LNs can be found
thereby affecting the adjuvant therapeutic plan and
possibly long-term survival [17, 18]. In addition, injecting
intratumorally allows lumpectomy with the radioguided
occult lesion localization (ROLL) technique in the same
procedure [19–21].
The use of a 1-day protocol or a 2-day protocol is often a
choice based on local preferences driven by logistic
considerations. In a 2-day protocol multiple patients can
be scheduled for lymphoscintigraphic imaging and sentinel
node procedures in the operating room. The advantage of
the 1-day protocol is that patients only require one hospital
visit and the radiation dose is minimized. Lowering the
dose of radiotracer from 370 MBq in the 2-day protocol to
120 MBq in the 1-day protocol represents a threefold
reduction in the radiation burden for both patients and
physicians.
In conclusion, there was no significant difference in the
success rate of SLNB in patients diagnosed with a
nonpalpable breast carcinoma between those treated in a
1-day protocol and those treated in a 2-day protocol. In our
hospital currently all patients diagnosed with a nonpalpable
Protocol Guide wire No guide wire Total p value
1-day protocol 23/29 (80%) 34/38 (89%) 57/67 (85%) 0.247
2-day protocol 14/15 (93%) 37/41 (90%) 51/56 (91%) 0.720
Total 37/44 (84) 71/79 (90%) 108/123 (88%)
p value 0.228 0.910
Table 3 Influence of the
presence of a guide wire on the
success rate of SLNB
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